Under accelerated review status, the FDA has approved Karyopharm Therapeutics’ (KPTI +4.3%)
Xpovio (selinexor) for the treatment of adults with relapsed/refractory
diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from
follicular lymphoma, after at least two lines of systemic therapy.
The agency OK’d the nuclear export inhibitor in July 2019 for multiple myeloma.
The company plans to file an application in Europe in 2021.
https://seekingalpha.com/news/3584990-fda-oks-expanded-use-of-karyopharms-selinexor
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.